SARS-CoV-2 Spike Binding Polypeptides via Virtual CDR Loops
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a critical need for specific antiviral therapeutic agents to prevent the transmission and treat COVID-19, as existing measures like quarantine and isolation are insufficient in managing the rapid spread of COVID-19 caused by SARS-CoV-2.
Innovation Solution
Development of polypeptides that specifically bind to the Spike glycoprotein of SARS-CoV-2, mimicking the binding properties of antibodies to inhibit viral entry into host cells, which are used in pharmaceutical compositions to treat COVID-19 patients and prevent transmission.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polypeptides specifically binding to SARS-CoV-2 Spike protein are developed, then antiviral therapeutic efficacy is improved, but manufacturing complexity increases
Solution Approach 1:
The patent creates simplified copies of antibody paratopes using polypeptides with virtual CDR loops that replicate the binding interface of natural antibodies. These polypeptides copy only the essential antigen-binding regions (CDR1, CDR2, CDR3) without requiring full antibody structures, enabling easier production while maintaining therapeutic efficacy against SARS-CoV-2 Spike protein
Solution Approach 2:
The invention modifies the structural parameters of antibody binding by using virtual CDR loops with specific length ranges (CDR1: 3-7 residues, CDR2: 3-7 residues, CDR3: 3-10 residues) and fixed framework regions. This parameter optimization enables the polypeptides to achieve high binding affinity and specificity for Spike protein while simplifying the manufacturing process compared to full-length antibodies
2Reliability
If polypeptides with high binding specificity to Spike protein are designed, then viral entry inhibition is improved, but structural complexity increases
Solution Approach 1:
The patent extracts only the essential antigen-binding components (CDR loops) from full antibody molecules to create minimal polypeptide structures. By taking out and isolating the CDR1, CDR2, and CDR3 regions that directly contact the Spike protein, the invention achieves high binding specificity without requiring the complex full antibody structure, including constant regions and Fc domains
Solution Approach 2:
The invention concentrates binding functionality in localized CDR loop regions with specific sequence characteristics and lengths. Each CDR loop is optimized independently (CDR1: 3-7 residues, CDR2: 3-7 residues, CDR3: 3-10 residues) to provide local binding specificity, while the framework regions provide stable but non-specific structural support, creating a polypeptide with high local binding quality but reduced overall structural complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptides effectively reduce SARS-CoV-2 Spike-mediated viral entry into cells, providing a targeted therapeutic approach to treat COVID-19 and prevent its transmission by specifically binding to the Spike protein.
Implementation Method 1
polypeptides that specifically bind to the Spike glycoprotein of SARS-CoV-2, mimicking the binding properties of antibodies to inhibit viral entry into host cells
Data Source
AI summary
The invention provides, in various embodiments, polypeptides that specifically bind to Spike glycoprotein of severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-2-Spike). The invention also provides, in various embodiments, fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors and host cells suitable for expressing the polypeptides, and methods for treating viral infections (e.g., COVID-19).